A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with doxorubicin, docetaxel, and cyclophosphamide (TAC). Chemotherapy affects cells that are dividing, whether they are tumor cells or healthy cells (including, bone marrow cells, hair follicle cells, and epithelial cells lining the gastrointestinal tract). ALRN-6924 is designed to stop cell division in healthy cells but not in tumor cells because they have a mutation of the TP53 gene. When this happens, tumor cells will still be destroyed by the chemotherapy but healthy cells that are not dividing may be spared from chemotherapy damage and the patient should have less side effects.

Study Overview

• Status: Terminated
• Conditions: Prevention of Chemotherapy-induced Myelosuppression
• Intervention / Treatment: Drug: ALRN-6924; Drug: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)

Detailed Description

This is a Phase 1b, open-label, single-arm, multicenter clinical trial for evaluation of safety, tolerability and chemoprotection effects of ALRN-6924 combined with chemotherapy in patients with TP53-mutated, HER2 negative breast cancer without distant organ metastases. All patients will receive the neoadjuvant or adjuvant chemotherapy regimen known as TAC. TAC consists of doxorubicin 50 mg/m2 IV infusion, docetaxel 75mg/m2 IV infusion and cyclophosphamide 500 mg/m2 IV infusion, given on Day 1 of every 3-week cycle for a total of 4-6 treatment cycles according to each patient's individual needs, individual institutional policies and standards of care, as well as investigator discretion. ALRN-6924 1.2 mg/kg will be administered on 3 consecutive days in each treatment cycle, Days 0-2. Prophylactic administration of G-CSF prior to the first instance of Grade 4 neutropenia is not allowed in Cycle 1. Myeloid growth factor support with filgrastim should be administered immediately if a patient is diagnosed with Grade 4 neutropenia.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Andres Brainsky, MD; Phone Number: 484-868-8286; Email: abrainsky@aileronrx.com

Study Locations

• Bosnia and Herzegovina
  • Banja Luka, Bosnia and Herzegovina, 71000
    • University Clinical Center of the Republic of Srpska
  • Mostar, Bosnia and Herzegovina, 88000
    • University Clinical Hospital Mostar
  • Sarajevo, Bosnia and Herzegovina, 71000
    • Clinical Center University of Sarajevo, Oncology Clinic
  • Tuzla, Bosnia and Herzegovina, 75000
    • University Clinical Center Tuzla
• Bulgaria
  • Panagyurishte, Bulgaria, 4500
    • MBAL University Hospital OOD
  • Plovdiv, Bulgaria, 4000
    • KOC (Complex Oncology Center) Plovdiv
• Serbia
  • Belgrade, Serbia, 11070
    • Klinicko Bolnicki Centar "Bezanijska Kosa"
  • Kragujevac, Serbia, 34000
    • Univerzitetski Klinicki centar Kragujevac
  • Sremska Kamenica, Serbia, 21204
    • Oncology Institute of Vojvodina
• United States
  • Florida
    • Tamarac, Florida, United States, 33321
      • Oncology and Hematology Associates of West Broward
  • North Carolina
    • Huntersville, North Carolina, United States, 28078
      • Southern Oncology Specialists
    • Wilson, North Carolina, United States, 27893
      • Regional Medical Oncolgy Center
  • Ohio
    • Canton, Ohio, United States, 44718
      • Gabrail Cancer Center
  • Pennsylvania
    • Gettysburg, Pennsylvania, United States, 17325
      • Pennsylvania Cancer Specialists & Resesrach Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Females and males, age ≥18years.
• Patients who, in the investigator's judgment, are able to understand and willing to comply with the requirements of this clinical trial and to provide written informed consent.
• Histologically confirmed diagnosis of HER2 negative breast cancer
• Candidate to receive chemotherapy with TAC regimen
• Presence of p53 mutation(s) in tumor tissue as assessed by next generation sequencing (NGS).
• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2
• Left ventricular ejection fraction > 55%.

• Laboratory results obtained within 14 days prior to the first study treatment administration (Cycle 1, Day 0) demonstrating:

  • Absolute neutrophil count (ANC) ≥ 1500 cells/μL (without granulocyte colony stimulating factor [G-CSF] support within 2 weeks prior to the first study treatment administration)
  • Platelet count ≥ 100,000/μL (without transfusion within 2 weeks prior to the first study treatment administration)
  • Hemoglobin ≥ 10.0 g/dL
  • AST, ALT, and alkaline phosphatase ≤ 2.5 x the upper limit of normal (ULN)
  • Serum bilirubin ≤ 1.5× ULN (patients with known Gilbert's disease who have serum bilirubin level ≤ 3× ULN may be enrolled.)
  • Patients who are not receiving therapeutic anticoagulation: Calculated creatinine clearance (CrCl) ≥ 30 mL/min (Cockcroft-Gault formula).
• Have not received prior chemotherapy or targeted systemic therapy for their breast cancer.

Exclusion Criteria:

• Known hypersensitivity to any component of study treatment.

• Prior chemotherapy for HER2 negative breast cancer.

  1. Presence of distant metastases. Nodal involvement is acceptable.

• Uncontrolled intercurrent illness including but not limited to:

  • Clinically significant, active, uncontrolled infection including human immunodeficiency virus (HIV), or hepatitis B or C

    • Patients with HIV must be on effective antiretroviral therapy for ≥ 4 weeks prior to enrollment and have HIV viral load < 400 copies/mL, have had no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the past 12 months, and have CD4+ count ≥ 350 cells/μL.
    • Patients with chronic hepatitis B virus (HBV) must be on antiviral therapy and have HBV viral load below the limits of detection.
    • Patients with hepatitis C virus (HCV) must be on or have completed antiviral therapy and have an HCV viral load below the limits of detection.
  • Uncontrolled hypertension
  • Uncontrolled diabetes mellitus
• Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling temporary pacemaker.
• Pregnant or lactating women.
• Hereditary angioedema of any severity or severe or life-threatening angioedema due to any cause.
• Treatment with an investigational agent for any indication within the shorter of 14 days or 5 half-lives, if the half-life is known.
• The required use of any concomitant medications that are predominantly cleared by hepatobiliary transporters, OATP members OATP1B1 and OATP1B3, on the day of the first ALRN-6924 infusion to within 48 hours after the last ALRN-6924 infusion in a treatment cycle. This criterion does not apply to the patients in the control group.
• Other medications, severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
• Clinically evident alopecia of any grade at screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: ALRN-6924 Dose plus TAC; ALRN-6924 plus Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Drug: ALRN-6924; ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).; Drug: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2); TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability of ALRN-6924 in combination with TAC chemotherapy	Proportion of patients with Common Terminology Criteria for Adverse Events (CTCAE) Grade 3/4 treatment emergent adverse events (TEAEs); proportion of patients with treatment-related adverse events and serious adverse events as assessed by NCI CTCAE v5.0 Clinical and laboratory adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). System Organ Class (SOC) and Preferred Term (PT) will be attached to the clinical database. AE severity will be graded using the CTCAE. All AEs will be summarized (incidence) and listed by the System Organ Class (SOC), preferred term, toxicity/severity grade, and causal relationship to study medication. In addition, separate summaries of SAEs and Grade 3 and 4 AEs will be presented.	Approximately 24 weeks
Chemoprotective effects of ALRN-6924 on bone marrow toxicities	Incidence and duration of Grade 4 neutropenia in Cycle 1 for each treatment cycle and all cycles combined	Approximately 3 weeks for each patient

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chemoprotective effects of ALRN-6924 on alopecia induced by TAC	Incidence of Grade 2 alopecia after treatment with ALRN-6924 plus TAC	Approximately 24 weeks
Chemoprotective effects of ALRN-6924 on neutropenia	Incidence rate of grade 4 neutropenia for each treatment cycle and all cycles combined	Approximately 24 weeks
Time to absolute neutrophil count (ANC) recovery in Cycle 1	Time in days from ANC nadir to recovery	3 weeks (cycle 1)
Depth of ANC nadir in Cycle 1	Lowest ANC count during cycle 1	3 weeks (cycle 1)
Chemoprotective effects of ALRN-6924 on Grade ≥3 neutropenia for each cycle and all cycles	CTCAE v5 grade 3 neutropenia	Approximately 24 weeks
Chemoprotective effects of ALRN-6924 on thrombocytopenia	CTCAE v5 grade ≥3 thrombocytopenia	Approximately 24 weeks
Chemoprotective effects of ALRN-6924 on anemia	CTCAE v5 grade ≥3 anemia	Approximately 24 weeks
Chemoprotective effects of ALRN-6924 on febrile neutropenia	Incidence of febrile neutropenia for each cycle and all cycles	Approximately 24 weeks
Chemoprotective effects of ALRN-6924 on the need for chemotherapy dose reductions	Number of dose reductions of chemotherapy due to chemotherapy-related toxicity for each cycle and all cycles	Approximately 24 weeks
Use of myeloid growth factors	Number of instances of granulocyte colony-stimulating factors (G-CSF) use to treat Grade 4 neutropenia for each cycle and all cycles	Approximately 24 weeks
Need for red blood cell transfusions	Number of red blood cell (RBC) transfusions during each cycle and all cycles	Approximately 24 weeks
Need for platelet transfusions	Number of platelet transfusions during each cycle and all cycles The ALRN-6924 PK profile with and without AC chemotherapy will be compared.	Approximately 24 weeks
PK of ALRN-6924	PK parameters (e.g., area-under-the-curve [AUC]) of ALRN-6924	Cycle 1 (each cycle is 21 days)
PK of ALRN-6924	PK parameters (e.g., maximum concentration [Cmax] of ALRN-6924	Cycle 1 (each cycle is 21 days)
PK of ALRN-6924	PK parameters (e.g., time of Cmax [tmax]) of ALRN-6924	Cycle 1 (each cycle is 21 days)
PK of ALRN-6924	PK parameters (e.g., half-life [t1/2]) of ALRN-6924	Cycle 1 (each cycle is 21 days)
Efficacy of chemotherapy	Tumor response after TAC chemotherapy: proportion of patients with pCR after completion of neoadjuvant chemotherapy and surgery, per local standard of care and institutional policies	Approximately 24 weeks

Collaborators and Investigators

• Sponsor: Aileron Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2023
• Primary Completion (Actual): February 22, 2023
• Study Completion (Actual): February 22, 2023

Study Registration Dates

• First Submitted: June 1, 2022
• First Submitted That Met QC Criteria: November 16, 2022
• First Posted (Actual): November 18, 2022

Study Record Updates

• Last Update Posted (Estimate): February 27, 2023
• Last Update Submitted That Met QC Criteria: February 24, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Breast cancer; p53 mutation; Alopecia; Neutropenia; ALRN-6924; Chemoprotection; Myelosuppression; Cell cycle arrest
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Docetaxel; Cyclophosphamide; Doxorubicin
• Other Study ID Numbers: ALRN-6924-1-05; 2022-000158-27 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No